Standard Biotools (LAB) Cost of Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Cost of Revenue data on file, last reported at $9.8 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $9.8 million, up 7.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.5 million (down 2.73% YoY), and the FY2025 annual result was $42.8 million, down 7.23% from the prior year.
• Cost of Revenue eased to $9.8 million in Q1 2026 per LAB's latest filing, from $12.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $21.4 million in Q1 2024 and troughed at $1.9 million in Q1 2022.
• A 5-year average of $12.6 million and a median of $12.8 million in 2023 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue surged 565.87% in 2023, then tumbled 57.04% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $15.9 million in 2022, then retreated by 6.45% to $14.8 million in 2023, then declined by 9.51% to $13.4 million in 2024, then retreated by 7.5% to $12.4 million in 2025, then slipped by 20.74% to $9.8 million in 2026.
• Business Quant data shows LAB's Cost of Revenue at $9.8 million in Q1 2026, $12.4 million in Q4 2025, and $10.1 million in Q3 2025.